文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

雾化两性霉素B预防机械通气COVID-19患者侵袭性肺曲霉病:回顾性队列研究

Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study.
PubMed 文献 · Crit Care Explor · 2022-05-09
一句话结论回顾性队列显示,雾化常规两性霉素B使机械通气COVID-19患者 probable/proven CAPA 发生率从67%降至27%(p=0.047),作者认为安全且可考虑作为预防,但需随机对照试验证实。

荷兰Ede大学附属综合医院17张床成人ICU的回顾性队列研究,连续纳入2021年1月25日至7月9日COVID-19有创机械通气患者,排除无需IMV或ICU间转运者;自2021年4月9日起对所有IMV患者每日雾化两性霉素B。39例可分析(预防组16例、非预防组23例),26例行支气管镜BAL。预防组probable/proven CAPA发生率显著低于非预防组(27% vs 67%,p=0.047),气管支气管病变、曲霉培养阳性、BAL半乳甘露聚糖阳性率亦显著降低;预防组无治疗相关不良事件、无proven CAPA。作者结论:雾化c-AmB安全,可考虑用于预防CAPA,但需RCT确认。

要点

  • 预防组probable/proven CAPA 27% vs 非预防组67%,p=0.047,Pearson卡方检验。
  • 预防组气管支气管病变9% vs 47%(p=0.040),曲霉培养阳性9% vs 53%(p=0.044),BAL半乳甘露聚糖阳性20% vs 60%(p=0.047)。
  • 预防组无治疗相关不良事件,无proven CAPA病例。
  • 作者认为雾化c-AmB在IMV COVID-19重症患者中安全,可考虑作为抗真菌预防以预防CAPA,但需RCT证实。
  • 研究为单中心回顾性队列,样本量39例(预防组16例、非预防组23例),26例行支气管镜BAL。

适用人群与场景

  • 荷兰Ede大学附属综合医院成人17张床ICU,2021年1月25日至2021年7月9日连续纳入的COVID-19有创机械通气(IMV)患者。
  • 排除不需要IMV或从其他ICU转入/转至其他ICU的患者。

诊断标准与关键阈值

  • 呼吸道培养曲霉阳性和/或不明原因呼吸恶化时行支气管镜肺泡灌洗(BAL)。
  • 比较probable和proven CAPA发生率。

处置流程与药物剂量

  • 自2021年4月9日起,对所有IMV患者每日雾化两性霉素B(常规两性霉素B,c-AmB)作为抗真菌预防。

研究设计与关键结果

  • 回顾性队列研究,39例插管COVID-19患者可分析,其中16例接受抗真菌预防、23例未接受;26例行支气管镜BAL。
  • 预防组probable/proven CAPA发生率显著低于非预防组(27% vs 67%;p=0.047)。
  • 预防组气管支气管病变发生率显著低于非预防组(9% vs 47%;p=0.040)。
  • 预防组曲霉培养阳性率显著低于非预防组(9% vs 53%;p=0.044)。
  • 预防组BAL半乳甘露聚糖阳性率显著低于非预防组(20% vs 60%;p=0.047)。
  • 接受抗真菌预防的患者中未发生治疗相关不良事件,无proven CAPA病例。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性;作者在结论中指出需随机对照试验证实。

对床旁实践的改变

  • 作者认为,在IMV COVID-19重症患者中雾化c-AmB安全,可考虑作为抗真菌预防以预防CAPA。
  • 作者指出需随机对照试验证实该结果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Despite high mortality rates of COVID-19-associated pulmonary aspergillosis (CAPA) in the ICU, antifungal prophylaxis remains a subject of debate. We initiated nebulized conventional amphotericin B (c-AmB) as antifungal prophylaxis in COVID-19 patients on invasive mechanical ventilation (IMV).

OBJECTIVES: To assess the CAPA incidence in COVID-19 patients on IMV treated with and without nebulized c-AmB as antifungal prophylaxis.

DESIGN SETTING AND PARTICIPANTS: Retrospective cohort study of consecutive COVID-19 patients admitted to our adult 17-bed ICU in a university-affiliated general hospital in Ede, The Netherlands, between January 25, 2021, and July 9, 2021. Patients not requiring IMV or transferred from or to another ICU were excluded. From April 9, 2021, daily nebulized amphotericin B in all patients on IMV was initiated.

MAIN OUTCOMES AND MEASURES: Bronchoscopy with bronchoalveolar lavage (BAL) was performed in case of positive cultures for Aspergillus from the respiratory tract and/or unexplained respiratory deterioration. Incidence of probable and proven CAPA was compared between patients treated with and without nebulized antifungal prophylaxis using Pearson chi-square test.

RESULTS: A total of 39 intubated COVID-19 patients could be analyzed, of which 16 were treated with antifungal prophylaxis and 23 were not. Twenty-six patients underwent bronchoscopy with BAL. In patients treated with antifungal prophylaxis, the incidence of probable/proven CAPA was significantly lower when compared with no antifungal prophylaxis (27% vs 67%; p = 0.047). Incidence of tracheobronchial lesions and positive Aspergillus cultures and BAL-galactomannan was significantly lower in patients treated with antifungal prophylaxis (9% vs 47%; p = 0.040, 9% vs 53%; p = 0.044, and 20% vs 60%; p = 0.047, respectively). No treatment-related adverse events and no case of proven CAPA were encountered in patients receiving antifungal prophylaxis.

CONCLUSIONS AND RELEVANCE: Nebulization of c-AmB in critically ill COVID-19 patients on IMV is safe and may be considered as antifungal prophylaxis to prevent CAPA. However, a randomized controlled trial to confirm this is warranted.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Melchers M, van Zanten ARH, Heusinkveld M, et al. Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study. Crit Care Explor. 2022. PMID: 35558738. doi:10.1097/CCE.0000000000000696

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。